Glenmark Pharmaceuticals: Attempt Out of Generic
We initiate our coverage on Glenmark Pharmaceuticals (GNP IN) (“Glenmark”)’s GNPIN 4.5% 8/21s (BB-/BB by S&P and Fitch, respectively)...
Glenmark Pharmaceuticals: Attempt Out of Generic
China Economics: RRR Cuts Proven Ineffective
China Economics: The China-US Trade War Escalation
China Economics: The Shantytown Mysteries
Noble Group: Sighting the End of the Restructuring Road
Tata Motors: A Tesla Capex
Bharti Airtel: Disciplined Deleveraging
Vedanta Resources: ZINCronized Deleveraging
Reliance Communications: Waiting to Exhale
Tata Steel: Lingering “Debt” Weight
Bharti Airtel Ltd: Third Time the Charm
JSW Steel: Upward Capex Revision Does Not Matter
Asian Credit Monitor: The Chinese Corporate Bond Default, Not a Systemic-Risk
The China-US Trade War: What Is the Next
Chinese Asset Management Industry: Monetary Policy and Regulations